ArticleClinical rheumatology2026
Regulatory role and mechanism of the probiotics on monosodium urate crystal-induced gout inflammation.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms of Gut Microbiota-Derived Metabolites in Treating Hyperuricemia: Natural Products as Interventions.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGout is an inflammatory disease characterized by the deposition of monosodium urate crystals in the joints. Probiotics have the potential effect of alleviating inflammation. The aim of this study was to investigate the potential beneficial effects of oral administration of the multi-strain probiotic Bifico and single-strain FN041 in a model of MSU-induced gout inflammation in mice and explore the underlying mechanism.
methodsTo investigate the mechanisms by which gut microbiota alleviates gouty inflammation, mice were orally administered Bifidobacterium, Lactobacillus FN041, colchicine, or distilled water daily for 21 days. Acute inflammation models were established by injecting monosodium urate (MSU) crystals into the peritoneal cavity and subcutaneous air pouch to induce peritonitis and localized gouty inflammation, respectively. Peritoneal lavage fluid, serum, and subcutaneous tissue were collected and analyzed by H&E staining, ELISA, immunohistochemistry, PCR, and Western blot to assess inflammatory responses.
resultsThe results confirmed that Bifico and FN041 reduced the inflammatory cell infiltration in the peritoneal cavity and synovial tissues of mice. The results of PCR and western blot analysis showed that Bifico and FN041 significantly downregulated the expression of NLRP3 and IL-1β, thereby alleviating gout inflammation. Immunohistochemical results also confirmed that Bifico and FN041 reduced the expression of inflammatory elements such as IL-1β, NLRP3, and caspase-1 in synovial tissue.
conclusionsIn conclusion, probiotics Bifico and FN041 reduced the inflammatory response in gout, with the potential mechanism being the regulation of the NLRP3/IL-1β pathway to control inflammation. Multi-strain Bifico has a stronger anti-inflammatory efficacy than single-strain FN041. Key Points • Probiotics Bifico and Limosilactobacillus reuteri FN041 effectively alleviated the inflammatory response in gout. • The anti-inflammatory effects of Bifico and FN041 are primarily mediated through the regulation of the NLRP3/IL-1β signaling pathway. • The multi-strain probiotic Bifico demonstrated a more pronounced anti-inflammatory efficacy compared to the single-strain probiotic FN041.
Indexed as
Identifiers
41569353What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.